Akebia Therapeutics Posts Q2 2025 Revenue of $62.5 Million, Achieves Net Income of $0.2 Million

Akebia Therapeutics reported Q2 2025 revenue of $62.5 million, driven by Vafseo and Auryxia sales. Vafseo revenue reached $13.3 million, a 55% increase from Q1. The company achieved profitability with a net income of $0.2 million, reversing an $8.6 million loss in Q2 2024. Akebia also completed patient enrollment for the VOICE trial and commenced the VOCAL trial to evaluate Vafseo's efficacy. The company maintained a strong cash position of $137.3 million, positioning it well for future funding initiatives.

Akebia Therapeutics Inc (AKBA) reported robust financial performance for the second quarter of 2025, with total revenues of $62.5 million, driven by strong sales of Vafseo and Auryxia. The company's net income for the quarter was $0.2 million, reversing an $8.6 million loss in the same period last year [2].

Vafseo, a medication for anemia in patients with chronic kidney disease (CKD), saw a significant increase in revenue, reaching $13.3 million in Q2 2025, a 55% increase from Q1. The company has been actively expanding patient access to Vafseo, with enrollment completed in the VOICE trial, a collaborative clinical trial with US Renal Care [1]. Additionally, Akebia initiated the VOCAL trial to evaluate the efficacy and safety of Vafseo compared to standard-of-care erythropoietin stimulating agents (ESAs) [2].

Akebia's Auryxia, a ferric citrate product, also contributed to the company's revenue, with net product revenues of $47.2 million in Q2 2025. Despite the loss of exclusivity on March 20, 2025, Akebia has not yet faced significant generic competition for Auryxia [2].

The company's research and development expenses increased to $11.0 million in Q2 2025, primarily due to increased clinical trial activities related to Vafseo and other programs. Akebia maintained a strong cash position of $137.3 million, positioning it well for future funding initiatives [2].

In terms of strategic growth initiatives, Akebia has secured commercial contracts with all key dialysis organizations, covering nearly 100% of dialysis patients, which supports future growth. The company is also working towards its goal to initiate the VALOR trial, a Phase 3 clinical trial to study the use of Vafseo for treating anemia in late-stage CKD patients who are not on dialysis, by the end of this year [2].

Overall, Akebia Therapeutics demonstrated strong financial performance and strategic progress in Q2 2025, positioning it well for future growth in the kidney disease treatment market.

References:
[1] https://www.gurufocus.com/news/3048364/akebia-therapeutics-inc-akba-q2-2025-earnings-call-highlights-record-revenue-and-strategic-growth-initiatives?mod=mw_quote_news&r=4bf001661e6fdd88d0cd7a5659ff9748
[2] https://ir.akebia.com/news-releases/news-release-details/akebia-therapeutics-reports-second-quarter-2025-financial